Novartis AG, listed on the NYSE:NVS, is a global healthcare company known for its innovative medicines and treatments. The company is a major player in the pharmaceutical industry, competing with giants like Pfizer and Roche. Novartis is set to release its third-quarter 2025 earnings on Tuesday, October 28th, before the market opens.
Wall Street anticipates Novartis to report earnings per share (EPS) of $2.26, while analysts project a slightly higher EPS of $2.28. The revenue forecast is approximately $13.87 billion, with analysts estimating a close $13.7 billion. These figures reflect the market's expectations for the company's financial performance in the quarter.
Novartis' stock opened at $130.48 on Friday, with a market capitalization of $275.64 billion. The stock has a price-to-earnings (P/E) ratio of 18.99, indicating how much investors are willing to pay for each dollar of earnings. The beta of 0.64 suggests moderate volatility compared to the market, meaning the stock is less likely to experience large price swings.
The company's financial health is evident in its current ratio of 0.82 and a quick ratio of 0.62, which measure its ability to cover short-term liabilities. The debt-to-equity ratio of 0.53 shows a balanced approach to financing, with a moderate level of debt compared to equity. The stock's fifty-day simple moving average is $127.56, while the 200-day average is $119.49, indicating a positive trend over the past year.
Novartis' valuation metrics include a price-to-sales ratio of 4.64 and an enterprise value to sales ratio of 5.11, reflecting the market's view of its revenue and total worth. The enterprise value to operating cash flow ratio of 13.44 highlights the company's cash flow efficiency. An earnings yield of 3.79% provides insight into the return on investment for shareholders.
